Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Debt Repayments (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Long-Term Debt Repayments for 6 consecutive years, with -$47000.0 as the latest value for Q2 2018.

  • On a quarterly basis, Long-Term Debt Repayments fell 166.2% to -$47000.0 in Q2 2018 year-over-year; TTM through Sep 2019 was -$47000.0, a 202.17% decrease, with the full-year FY2019 number at $565000.0, changed N/A from a year prior.
  • Long-Term Debt Repayments was -$47000.0 for Q2 2018 at Niagen Bioscience, down from $47000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $424000.0 in Q3 2017 to a low of -$47000.0 in Q2 2018.
  • A 3-year average of $83485.0 and a median of $55901.0 in 2016 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: surged 658.48% in 2017, then tumbled 166.2% in 2018.
  • Niagen Bioscience's Long-Term Debt Repayments stood at $57733.0 in 2016, then dropped by 20.32% to $46000.0 in 2017, then tumbled by 202.17% to -$47000.0 in 2018.
  • Per Business Quant, the three most recent readings for NAGE's Long-Term Debt Repayments are -$47000.0 (Q2 2018), $47000.0 (Q1 2018), and $46000.0 (Q4 2017).